ALLIANCES (Otsuka) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended																											12 Months Ended					12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended		12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013 Abilify [Member]	Dec. 31, 2012 Abilify [Member]	Dec. 31, 2011 Abilify [Member]	Dec. 31, 2013 Oncology Territory [Member] Sprycel and Ixempra [Member]	Dec. 31, 2012 Oncology Territory [Member] Sprycel and Ixempra [Member]	Dec. 31, 2011 Oncology Territory [Member] Sprycel and Ixempra [Member]	Dec. 31, 2013 Alliance Partners [Member]	Dec. 31, 2012 Alliance Partners [Member]	Dec. 31, 2011 Alliance Partners [Member]	Dec. 31, 2013 Otsuka [Member]	Dec. 31, 2012 Otsuka [Member]	Dec. 31, 2011 Otsuka [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member]	Dec. 31, 2012 Otsuka [Member] United States [Member] Abilify [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] Abilify [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales up to 2 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 2 Point 7 billion and 3 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 3 Point 2 billion and 3 Point 7 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 3 Point 7 billion and 4 Point 0 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales between 4 Point 0 billion and 4 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Annual net sales over 4 Point 2 billion [Member]	Dec. 31, 2013 Otsuka [Member] United States [Member] Abilify [Member] Extension payment [Member]	Dec. 31, 2012 Otsuka [Member] United States [Member] Abilify [Member] Extension payment [Member]	Apr. 30, 2009 Otsuka [Member] United States [Member] Abilify [Member] Extension payment [Member]	Dec. 31, 2012 Otsuka [Member] United States [Member] Abilify [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2011 Otsuka [Member] United States [Member] Abilify [Member] Upfront, milestone and other licensing payments [Member]	Dec. 31, 2013 Otsuka [Member] France, Germany, Spain, United Kingdom and Italy [Member] Abilify [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Operating expense up to $175 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Operating expenses over $175 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales up to $400 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales up to $400 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $400 and $600 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $400 and $600 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $600 and $800 million [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $600 and $800 million [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $800 million and $1 billion [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales between $800 million and $1 billion [Member]	Dec. 31, 2013 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales over $1 billion [Member]	Dec. 31, 2012 Otsuka [Member] Oncology Territory [Member] Sprycel and Ixempra [Member] Annual net sales over $1 billion [Member]
Alliances Statement [Line Items]
Percentage of third-party product sales recognized when BMS is the principal in the end customer sale	100.00%								100.00%
Net product sales									$ 12,304	$ 13,654	$ 17,622							$ 4,417	$ 6,124	$ 10,460	$ 1,543	$ 1,386	$ 1,181
Alliance and other revenues									4,081	3,967	3,622	1,840	2,340	2,303				3,804	3,748	3,548	1,840	2,340	2,303
Total Revenues	4,441	4,065	4,048	3,831	4,191	3,736	4,443	5,251	16,385	17,621	21,244	2,289	2,827	2,758				8,221	9,872	14,008	3,383	3,726	3,484
Payments to/(from) alliance partner- Cost of products sold																		1,356	1,706	2,823
Payments to/(from) alliance partner - Marketing, selling and administrative																		(125)	(80)	(9)
Payments to/(from) alliance partner - Advertising and product promotion																		(58)	(97)	(86)
Payments to/(from) alliance partner - Research and development																		(140)	4	89
Payments to/(from) alliance partners - Other (income)/expense																		313	489	317
Net income attributable to noncontrolling interest, pre-tax																		36	844	2,323
Receivables - from alliance partners	1,122				857				1,122	857
Accounts payable - to alliance partners	1,396				1,052				1,396	1,052
Deferred income	1,525				4,849				1,525	4,849								5,089	4,647
Deferred income from alliances included in liabilities related to assets held-for-sale	3,671								3,671
Percentage of net sales recognized from alliance																					34.00%	51.50%	53.50%				50.00%	20.00%	7.00%	2.00%	1.00%	20.00%						65.00%
Payment to extend term of commercialization agreement																																			400
Percentage of net sales payable to alliance partner																								1.50%																	65.00%	30.00%	12.00%	5.00%	3.00%	3.00%	2.00%	2.00%	1.00%	1.00%
Percentage of operating expense reimbursements from alliance																								30.00%															20.00%	1.00%
Range of sales at which a given percentage will be paid to alliance partner - minimum																												2,700	3,200	3,700	4,000	4,200											400		600		800		1,000
Range of sales at which a given percentage will be paid to alliance partner - maximum																											2,700	3,200	3,700	4,000	4,200										400		600		800		1,000
Amount of operating expense at or below which alliance partner will reimburse given percentage																																							175
Amount of operating expense over which alliance partner will reimburse given percentage																																								175
Cost of products sold - Oncology fee															295	138	134
Cost of products sold - Royalties																								86	78	72
Cost of products sold - Amortization of intangible assets									858	607	353																									5	6
Cost of products sold - Cost of product supply																					135	153	145
Cost reimbursements to/(from) alliance partner																					(10)	(47)	(45)
Other assets - extension payment	1,428				904				1,428	904																							87	153
Amortization of the extension payment																					$ 66	$ 66	$ 66